Technical Articles

Lokivetmab
Lokivetmab 的药理机制与临床应用研究进展
Research progress on pharmacological mechanism and clinical application of Lokivetmab
发布时间 2025-07-21
Lokivetmab is a monoclonal antibody against canine derived interleukin-31 (IL-31), a novel targeted biological agent developed through hybridoma or recombinant DNA technology, aimed at specifically blocking the IL-31 mediated itch signaling pathway.
View details
  • Immunity/Inflamma
  • Lokivetmab
Total 1
  • 1
Go to
UA
Link：
Products
Application
Cell FactorTarget Proteins
Custom Services
Custom Protein Expression ServicesCustom SPR Services
About Us
PromotionTechnical ArticlesProduct ApplicationFAQsCitationsAbout Us
We Media：
Facebook Linkedin YouTube X Thraeds Pinterest
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
 Business license (three certificates in one)
Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.